Compare NABL & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NABL | MDXG |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 945.6M | 530.2M |
| IPO Year | 2021 | 2007 |
| Metric | NABL | MDXG |
|---|---|---|
| Price | $3.64 | $3.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $8.31 | ★ $9.00 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $511,430,000.00 | $418,630,000.00 |
| Revenue This Year | $11.04 | N/A |
| Revenue Next Year | $8.53 | $13.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 9.71 | ★ 19.99 |
| 52 Week Low | $3.24 | $3.03 |
| 52 Week High | $9.04 | $7.99 |
| Indicator | NABL | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 33.73 | 49.42 |
| Support Level | $3.24 | $3.45 |
| Resistance Level | $5.22 | $7.39 |
| Average True Range (ATR) | 0.35 | 0.12 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 18.04 | 51.43 |
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.